TD 0714

Drug Profile

TD 0714

Alternative Names: TD0714

Latest Information Update: 28 Oct 2016

Price : $50

At a glance

  • Originator Theravance Biopharma
  • Class Antihypertensives; Cardiovascular therapies
  • Mechanism of Action Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cardiovascular disorders; Kidney disorders

Most Recent Events

  • 25 Oct 2016 Pharmacokinetics and adverse events data from a phase I multi-ascending dose trial in Kidney disorders and Cardiovascular disorders released by Theravance
  • 25 Oct 2016 Theravance Biopharma plans a phase I trial for Cardiovascular disorders (IV)
  • 09 Mar 2016 Pharmacokinetics and adverse events data from a phase I trial in Kidney disorders and Cardiovascular disorders released by Theravance
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top